Meropenem NEW
| Price | $42 | $58 |
| Package | 50mg | 100mg |
| Supply Ability: | 10g |
| Update Time: | 2026-06-02 |
Product Details
| Product Name: Meropenem | CAS No.: 96036-03-2 |
| Purity: 99.71% | Supply Ability: 10g |
| Release date: 2026/06/02 |
Product Introduction
Bioactivity
| Name | Meropenem |
| Description | Meropenem (SM 7338) is a synthetic carbapenem antibiotic with broad-spectrum antibacterial activity. It exerts a bactericidal effect by inhibiting the synthesis of peptidoglycan in the bacterial cell wall and is active against a wide range of Gram-positive, Gram-negative, and anaerobic bacteria. Meropenem is active against both susceptible and resistant Neisseria gonorrhoeae (MIC values of 0.02–0.06 mg/mL), Haemophilus influenzae (MIC: 0.03–0.12 mg/mL), and Klebsiella pneumoniae (MIC: 0.015–0.12 mg/mL). Meropenem can be used for constructing bacterial infection models and screening for antimicrobial activity. |
| Kinase Assay | Complementation of SCR7 Inhibition with Puri?ed Ligase IV: Complementation experiment is carried out by adding increasing concentrations of puri?ed Ligase IV/XRCC4 complex (30, 60, and 120 fmol) along with the oligomeric DNA substrates (5' compatible and 5'-5' noncompatible ends) to the SCR7-treatedextracts. Reactions are incubated for 2 h at 25℃. The reaction products are then resolved on 8% denaturing PAGE. The gel is dried and exposed and the signal is detected with a PhosphorImager and analyzed with Multi Gauge (V3.0) software. |
| In vitro | Methods: Clinical isolates of NDM-1-producing Escherichia coli ZC-YN3, along with strains producing NDM-5 and NDM-9, were tested against monotherapy with Meropenem or Magnolol, or combination therapy with Meropenem + Magnolol (32 μg/mL) to determine the minimum inhibitory concentration (MIC). Results: Meropenem monotherapy MIC: 16 μg/mL (against ZC-YN3); Magnolol monotherapy MIC: >1024 μg/mL (no direct antibacterial activity); Meropenem + Magnolol combination MIC: 4 μg/mL (against ZC-YN3), representing a 4-fold reduction. [1] Methods: Human primary alveolar epithelial cells (HPAEpiC) were infected with PAO1 strain after mechanical stretching simulated by the FlexCell system. Drugs (meropenem at 5×MIC and 0.5×MIC) were added 2 hours post-infection. Bacterial load was assessed at 4 and 8 hours post-infection. Results: Meropenem effectively reduced bacterial load. [2] |
| In vivo | Methods: C57BL/6J mice were mechanically ventilated and infected with PAO1 strain via tracheal inoculation. Meropenem monotherapy was administered via intraperitoneal injection at 4 hours and 16 hours post-infection. Results: Meropenem monotherapy significantly reduced bacterial load in both the lungs and systemic tissues [2]. |
| Storage | Keep away from moisture,Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (10.43 mM), Sonication is recommended. DMSO : 100 mg/mL (260.78 mM), Sonication is recommended. Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : 5 mg/mL (13.04 mM), Sonication is recommended. |
| Keywords | β-lactamases | β-Lactamase | SM-7338 | SM7338 | parenteral | neutropenia | Meropenem | Inhibitor | inhibit | Gram-positive | Gram-negative | DHP-1 | D-alanyl-D-alanine carboxypeptidase DacB | carbapenem | Bacterial | Antibiotic | anaerobic |
| Inhibitors Related | Neomycin sulfate | Adipic dihydrazide | Levulinic acid | D(+)-Raffinose pentahydrate | Sulfamethoxazole sodium | Terbinafine hydrochloride | Doxycycline | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate | BES |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | ReFRAME Related Library | EMA Approved Drug Library | Drug Repurposing Compound Library | NO PAINS Compound Library | FDA-Approved Drug Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Infection Compound Library | NMPA-Approved Drug Library | Human Metabolite Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $990.00 |
VIP2Y
|
HEBEI SHENGSUAN CHEMICAL INDUSTRY CO.,LTD
|
2026-06-08 | |
|
VIP6Y
|
RongNa Biotechnology Co.,Ltd
|
2026-06-08 | ||
|
VIP2Y
|
Shaanxi Xianhe Biotech Co., Ltd
|
2026-06-08 | ||
|
VIP6Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2026-06-08 | ||
| $58.00 |
VIP2Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $58.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-06-02 | |
| $30.00 |
VIP6Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2026-05-28 | |
| $1.00 |
Hebei Chuanghai Biotechnology Co., Ltd
|
2026-03-20 | ||
| $1.00 |
VIP7Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2026-02-02 | |
| $8.00 |
VIP3Y
|
Henan Fengda Chemical Co., Ltd
|
2025-09-25 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY